Exercise vs control
Adverse events · people with Parkinson's disease
1 finding from 1 review
- no estimate extracted8 studies · 1242 participantsVery low
Findings
What do systematic reviews say?
9 questions · 9 findings · 3 reviews · Movement Disorders
No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 2 · 22.2%Low 1 · 11.1%Moderate 4 · 44.4%High 1 · 11.1%
Summary of findings for education vs control
Adverse events · people with Parkinson's disease
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings for exercise plus education vs control
Adverse events · people with Parkinson's disease
1 finding from 1 review
- no estimate extracted2 studies · 343 participantsVery low
Summary of findings: levodopa vs placebo
Dropouts due to adverse events · patients with restless legs syndrome
Summary of findings: levodopa showed no clear difference in dropouts due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- OR 0.73 [0.05, 11.34]6 studies · 109 participantsModerate
Summary of findings: levodopa vs other dopamine agonists
Adverse effects (drop‐outs due to adverse effects4) · patients with restless legs syndrome
Summary of findings: levodopa probably leads to lower number of drop outs due to adverse events compared with other dopamine agonists (moderate certainty).
1 finding from 1 review
- OR 0.593 studies · 504 participantsModerate
Dopamine agonist vs placebo
Withdrawals due to adverse events · patients with restless legs syndrome according to IRLSSG, 18 years or older
Summary of findings: dopamine agonists leads to higher number of dropouts due to adverse events compared with placebo (high certainty).
1 finding from 1 review
- Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes onlyOR 1.82 [1.35, 2.45]34 studies · 7054 participantsHigh
Dopamine agonist vs levodopa
Adverse effects (drop‐outs due to adverse effects4) · patients with restless legs syndrome
Summary of findings: dopamine agonists probably leads to higher number of drop outs due to adverse events compared with levodopa (moderate certainty).
1 finding from 1 review
- Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes onlyOR 1.73 studies · 504 participantsModerate
Dopamine agonist vs levodopa
Number of participants reporting an adverse event · patients with restless legs syndrome
Summary of findings: dopamine agonists showed no clear difference in number of patients experiencing adverse events compared with levodopa (moderate certainty).
1 finding from 1 review
- Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes onlyOR 2.87 [0.43, 19]3 studies · 461 participantsModerate
Summary of findings for cholinesterase inhibitors vs placebo
Rate of adverse events excluding falls (per person year) · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to higher rate of adverse events excluding falls (per person year) compared with placebo (low certainty).
1 finding from 1 review
- Rate ratio 1.6 [1.28, 2.01]2 studies · 175 participantsLow